TT-00420 Monotherapy in Refractory Cholangiocarcinoma: Phase 1 Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
At the ESMO 23rd World Congress on Gastrointestinal Cancer (ESMO GI 2021), Dr. S. Piha-Paul and colleagues from MD Anderson Cancer Center presented the results of a Phase 1 clinical trial evaluating the novel multikinase inhibitor TT-00420.
Study Design: TT-00420 Phase 1 Trial
The study evaluated TT-00420 as a monotherapy in patients with advanced refractory solid tumors, including a specific cohort of patients with cholangiocarcinoma (bile duct cancer).
- Cholangiocarcinoma Cohort (N=9):
- Median of 3 prior lines of therapy.
- 88.9% had intrahepatic cholangiocarcinoma.
- 77.8% (N=7) were positive for FGFR2 fusions or rearrangements.
Patients received oral TT-00420 at doses ranging from 1 mg to 5 mg in 28-day cycles.
Key Efficacy Results
In the subset of patients with FGFR2-positive cholangiocarcinoma (N=5 evaluable):
- Partial Response (PR): 2 patients.
- Stable Disease (SD): Observed in several patients, with one patient continuing treatment for 9 months before undergoing surgical resection.
- Overall, antitumor activity was observed across all evaluable patients in this cohort.
Safety Profile
The most common adverse events (incidence >20%) included:
- Hypertension
- Diarrhea and Vomiting
- Hand-Foot Syndrome
- Nausea
These side effects were generally manageable through dose reductions or standard supportive care.
Conclusion
The researchers concluded that TT-00420 monotherapy shows encouraging preliminary efficacy in patients with heavily pretreated, FGFR2-positive advanced cholangiocarcinoma. These findings support further clinical investigation to determine the drug's role in the evolving treatment landscape for bile duct cancers.
Source: Annals of Oncology - TT-00420 Phase 1 Results
#BiliaryTractCancer #Cholangiocarcinoma #TT00420 #FGFR2 #MultikinaseInhibitor #CancerResearch #ESMOGI2021
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4